Journal of Immunobiology

ISSN: 2476-1966

Open Access

Charles J Malemud

University Hospitals Cleveland Medical Center,
Foley Medical Building, 2061 Cornell Road, Room 207, Cleveland, OH 44106-5076

  • Short Communication
    Treatment of SLE and Secondary Sjogren’s Syndrome with Belimumab
    Author(s): Riaz Ahmad, Charles J Malemud and Ali D AskariRiaz Ahmad, Charles J Malemud and Ali D Askari

    Belimumab neutralizes the soluble form of B-cell activating factor and is FDA-approved for treating Systemic Lupus Erythematosus (SLE). In this retrospective analysis 16 female SLE patients had been treated with belimumab according to FDA guidelines along with any immunosuppressive drugs or antimalarial drugs they had previously been prescribed, in addition to prednisone. Thirteen of 16 patients presented with serologic evidence of positive anti-nuclear antibody titer while several other SLE patients also had clinical evidence of secondary Sjogren’s Syndrome (2°SS), the latter supported by sicca symptoms and positive anti-Sjogren’s-syndrome-related antigen A antibody titer. Changes in the SLE symptoms after belimumab therapy was assessed by the recipient’s responses on the Short Form-36 questionnaire. Ten of the 16 SLE patients reported a decrease in arthralgias .. Read More»
    DOI: 10.4172/2476-1966.1000112

    Abstract PDF

Relevant Topics


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward